Lenalidomide Ranbaxy (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, leading to the targeted degradation of transcription factors Ikaros and Aiolos. This action modifies cytokine production, boosts T‑cell and natural‑killer cell activity, blocks new blood‑vessel formation, and induces programmed cell death in malignant plasma cells and dysplastic bone‑marrow cells.

The specific dose and schedule of Lenalidomide Ranbaxy are determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Healthcare providers follow approved labeling and clinical guidelines to individualize therapy.

Lenalidomide is classified as contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential must use effective contraception before, during, and after treatment. Safety during breastfeeding has not been established, and breastfeeding is generally discouraged while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The primary alternative to lenalidomide in many hematologic indications is pomalidomide, another immunomodulatory agent with a similar mechanism but a different safety profile and potency. Lenalidomide is often used earlier in treatment sequences, while pomalidomide may be reserved for patients who have progressed after lenalidomide therapy.

Lenalidomide Ranbaxy should be stored at temperatures below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Lenalidomide Ranbaxy is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablets are swallowed whole with water and should be taken at the same time each day to maintain consistent drug levels.

The most serious risks include venous thromboembolism (blood clots), severe neutropenia or thrombocytopenia that can lead to infections or bleeding, and the potential development of secondary primary malignancies. Patients should be monitored closely for these events throughout therapy.

Lenalidomide should not be used by individuals who are pregnant, have uncontrolled infections, or have a known hypersensitivity to lenalidomide or any of its excipients. Patients with severe renal impairment may require dose adjustments, and those with a history of thrombotic events should be evaluated carefully before starting therapy.